Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: A randomised, placebo-controlled phase 2 trial

Alzheimer's Research and Therapy

Volumn 3, Issue 2, 2011, Pages

  Piette, François ^a   Belmin, Joël ^a,b   Vincent, Hélène ^a   Schmidt, Nicolas ^c   Pariel, Sylvie ^a   Verny, Marc ^b   Marquis, Caroline ^b   Mely, Jean ^d   Hugonot Diener, Laurence ^e   Kinet, Jean Pierre ^f   Dubreuil, Patrice ^g,h,i,j   Moussy, Alain ^j   Hermine, Olivier ^k  

^a HÔPITAL CHARLES FOIX   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c Centre d'Investigation Libéral des Troubles de Mémoire   (France)

^d Service de Néonatologie Centre Hospitalier de la Région de Saint Omer   (France)

^e MEDFORMA   (France)

^f HARVARD MEDICAL SCHOOL   (United States)

^g AIX MARSEILLE UNIVERSITY   (France)

^h INSTITUT PAOLI CALMETTES   (France)

ⁱ AIX MARSEILLE UNIVERSITY   (France)

^j AB Science   (France)

^k ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; GALANTAMINE; MASITINIB; MEMANTINE; PLACEBO; RIVASTIGMINE;

ADD ON THERAPY; AGED; ALZHEIMER DISEASE; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTHRALGIA; ARTICLE; ASSESSMENT SCALE COGNITIVE SUBSCALE; ASTHENIA; BALANCE DISORDER; BRONCHITIS; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; EYELID EDEMA; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; LEUKOPENIA; MALE; METABOLIC DISORDER; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; VOMITING;

EID: 79957803165     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt75     Document Type: Article

References (31)

1. Global prevalence of dementia: a Delphi consensus study. CP Ferri M Prince C Brayne H Brodaty L Fratiglioni M Ganguli K Hall K Hasegawa H Hendrie Y Huang A Jorm C Mathers PR Menezes E Rimmer M Scazufca, Lancet 2005 366 2112 2117 16360788 (Pubitemid 41797645)
2. Oligomers of beta-amyloid are sequestered into and seed new plaques in the brains of an AD mouse model. RC Gaspar SA Villarreal N Bowles RW Hepler JG Joyce PJ Shughrue, Exp Neurol 2010 223 394 400 10.1016/j.expneurol.2009.09.001 19744481
3. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. J Naslund V Haroutunian R Mohs KL Davis P Davies P Greengard JD Buxbaum, JAMA 2000 283 1571 1577 10.1001/jama.283.12.1571 10735393 (Pubitemid 30161512)
4. Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy. E Zotova JA Nicoll R Kalaria C Holmes D Boche, Alzheimers Res Ther 2010 2 1 10.1186/alzrt24 20122289
5. Systemic inflammation and disease progression in Alzheimer disease. C Holmes C Cunningham E Zotova J Woolford C Dean S Kerr D Culliford VH Perry, Neurology 2009 73 768 774 10.1212/WNL.0b013e3181b6bb95 19738171
6. The role of inflammation in Alzheimer's disease. EE Tuppo HR Arias, Int J Biochem Cell Biol 2005 37 289 305 10.1016/j.biocel.2004.07.009 15474976 (Pubitemid 39330191)
7. Brain mast cells link the immune system to anxiety-like behavior. KM Nautiyal AC Ribeiro DW Pfaff R Silver, Proc Natl Acad Sci USA 2008 105 18053 18057 10.1073/pnas.0809479105 19004805
8. Critical role of mast cells in inflammatory diseases and the effect of acute stress. TC Theoharides DE Cochrane, J Neuroimmunol 2004 146 1 12 10.1016/j.jneuroim.2003.10.041 14698841 (Pubitemid 38032950)
9. Mast cells migrate from blood to brain. AJ Silverman AK Sutherland M Wilhelm R Silver, J Neurosci 2000 20 401 408 10627616 (Pubitemid 30220526)
10. The essential role of mast cells in orchestrating inflammation. JP Kinet, Immunol Rev 2007 217 5 7 10.1111/j.1600-065X.2007.00528.x 17498047
11. Abeta peptides can enter the brain through a defective blood-brain barrier and bind selectively to neurons. PM Clifford S Zarrabi G Siu KJ Kinsler MC Kosciuk V Venkataraman MR D'Andrea S Dinsmore RG Nagele, Brain Res 2007 1142 223 236 17306234 (Pubitemid 46413194)
12. Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease. AM Hartz DS Miller B Bauer, Mol Pharmacol 2010 77 715 723 10.1124/mol.109.061754 20101004
13. Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. GL Bowman JA Kaye M Moore D Waichunas NE Carlson JF Quinn, Neurology 2007 68 1809 1814 10.1212/01.wnl.0000262031.18018.1a 17515542 (Pubitemid 46791393)
14. Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia? JM Wardlaw PA Sandercock MS Dennis J Starr, Stroke 2003 34 806 812 10.1161/01.STR.0000058480.77236.B3 12627547
15. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. P Dubreuil S Letard M Ciufolini L Gros M Humbert N Casteran L Borge B Hajem A Lermet W Sippl E Voisset M Arock C Auclair PS Leventhal CD Mansfield A Moussy O Hermine, PLoS One 2009 4 7258 10.1371/journal.pone.0007258 19789626
16. Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study. J Tebib X Mariette P Bourgeois RM Flipo P Gaudin X Le Loet P Gineste L Guy CD Mansfield A Moussy P Dubreuil O Hermine J Sibilia, Arthritis Res Ther 2009 11 95 10.1186/ar2740 19549290
17. Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics. M Humbert F de Blay G Garcia A Prud'homme C Leroyer A Magnan JM Tunon-de-Lara C Pison M Aubier D Charpin I Vachier A Purohit P Gineste T Bader A Moussy O Hermine P Chanez, Allergy 2009 64 1194 1201 10.1111/j.1398-9995.2009.02122.x 19614621
18. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. N Takayama N Sato SG O'Brien Y Ikeda S Okamoto, Br J Haematol 2002 119 106 108 10.1046/j.1365-2141.2002.03881. x 12358909 (Pubitemid 35176504)
19. Treatment of Alzheimer's disease: current and future therapeutic approaches. JL Cummings, Rev Neurol Dis 2004 1 60 69 16400259
20. Amyloid beta peptides trigger CD47-dependent mast cell secretory and phagocytic responses. N Niederhoffer R Levy E Sick P Andre G Coupin Y Lombard JP Gies, Int J Immunopathol Pharmacol 2009 22 473 483 19505377
21. Corticotropin-releasing hormone and brain mast cells regulate blood-brain-barrier permeability induced by acute stress. P Esposito N Chandler K Kandere S Basu S Jacobson R Connolly D Tutor TC Theoharides, J Pharmacol Exp Ther 2002 303 1061 1066 10.1124/jpet.102.038497 12438528 (Pubitemid 35424390)
22. Brain mast cell degranulation regulates blood-brain barrier. X Zhuang AJ Silverman R Silver, J Neurobiol 1996 31 393 403 10.1002/(SICI)1097-4695(199612) 31:4<393::AID-NEU1>3.0.CO;2-4 8951099 (Pubitemid 26404988)
23. Modulation of microglia by stem cell factor. SC Zhang S Fedoroff, J Neurosci Res 1998 53 29 37 10.1002/(SICI)1097-4547(19980701)53:1<29::AID- JNR4>3.0.CO;2-L 9670990 (Pubitemid 28308979)
24. Beta-amyloid protein (25-35) disrupts hippocampal network activity: role of Fyn-kinase. F Pena B Ordaz H Balleza-Tapia R Bernal-Pedraza A Marquez-Ramos L Carmona-Aparicio M Giordano, Hippocampus 2010 20 78 96 19294646
25. Phosphorylation of tau by fyn: implications for Alzheimer's disease. G Lee R Thangavel VM Sharma JM Litersky K Bhaskar SM Fang LH Do A Andreadis G Van Hoesen H Ksiezak-Reding, J Neurosci 2004 24 2304 2312 10.1523/JNEUROSCI.4162-03. 2004 14999081 (Pubitemid 38314562)
26. Rapid tyrosine phosphorylation of neuronal proteins including tau and focal adhesion kinase in response to amyloid-beta peptide exposure: involvement of Src family protein kinases. R Williamson T Scales BR Clark G Gibb CH Reynolds S Kellie IN Bird IM Varndell PW Sheppard I Everall BH Anderton, J Neurosci 2002 22 10 20 11756483 (Pubitemid 34033478)
27. Platelet-derived growth factor induces the beta-gamma-secretase-mediated cleavage of Alzheimer's amyloid precursor protein through a Src-Rac-dependent pathway. D Gianni N Zambrano M Bimonte G Minopoli L Mercken F Talamo A Scaloni T Russo, J Biol Chem 2003 278 9290 9297 10.1074/jbc.M211899200 12645527 (Pubitemid 36800413)
28. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. T Erkinjuntti A Kurz S Gauthier R Bullock S Lilienfeld CV Damaraju, Lancet 2002 359 1283 1290 10.1016/S0140-6736(02)08267-3 11965273 (Pubitemid 34310633)
29. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. GK Wilcock S Lilienfeld E Gaens, BMJ 2000 321 1445 1449 10.1136/bmj.321.7274.1445 11110737
30. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. C Paul B Sans F Suarez P Casassus S Barete F Lanternier C Grandpeix-Guyodo P Dubreuil F Palmerini CD Mansfield P Gineste A Moussy O Hermine O Lortholary, Am J Hematol 2010 85 921 925 10.1002/ajh.21894 21108325
31. Masitinib for the treatment of canine atopic dermatitis: a pilot study. J Daigle A Moussy CD Mansfield O Hermine, Vet Res Commun 2009 34 51 63 20033487